After the Covid-19 outbreak, Swiss Robot decided to use the technical advantages of their existing prototype to develop a sterilization robot for hospitals and similar institutions in a short time.
If you wish to skip the registration process via the platform, please contact me directly: firstname.lastname@example.org
The following brochure can be download as a pdf under "Documents" to view it in higher quality
Download Link for the following presentation (please copy&paste in your browser):
Swiss Robot AG (CH-Lucerne) with equity capital of CHF 12,000,000, divided into 30,000,000 registered shares, develops highly innovative service robots for commercial use in the following areas on the basis of its worldwide protected patent:
Large glass and smooth building facades
Tall ship hulls
Solar and PV systems
Silo and large tank systems
Variety of special and individual applications
The patent value for this disruptive technology was € 30.3 million at the time of its registration.
Building on this, approx. CHF 10 million has been invested in the development and creation of the prototype FR-1 for glass facade and PV system cleaning as capitalized R&D costs in recent years.
In order to optimize the existing prototype for the desired performance and quality parameter parameters, improvements are required to accelerate the drive on vertical glass surfaces and to improve brush integration.
With the outbreak of the global corona pandemic, the management and development partners of Swiss Robot AG recognized that the existing level of development for the prototype FR-1 would immediately make it possible to use the drive on horizontal, smooth floors and use this as the basis for setting up a disinfection robot for clinics, schools, commercial or shared rooms, corridors, etc. The decisive advantage over competing products is the suction power of the drive feet, which should actually bring in their attraction for vertical glass surfaces on skyscrapers, but can now also be used as an ideal basis for useful structures on the horizontal level without falling over.
The fight against viruses and bacteria will be of great importance for global social development, not only in the current pandemic phase but also in the future. The market for technological innovations that support people in the fight against viruses and bacteria will continue to grow and will be significantly shaped by robotic. Today, viruses and bacteria are primarily eliminated through the use of disinfectants, combined with a high level of manual effort, especially in the medical field. In some cases, bacteria are combated by UV-C radiation, which is very dangerous for the human eye and is therefore used with small self-driving robots in hospitals. However, due to their low height, these cannot be as effective as if the light source were emitted at a higher room height. On the other hand, they cannot achieve a greater radiation level, since they would have no hold and would fall over without the suction mechanism.
With the FTS Medical Robot, Swiss Robot will effectively combine both methods of control. Building on the drive of the prototype for facade cleaning FR-1, the FTS Medical Robot will have a 1.60 m high telescopic construction with UV-C lamps and four fold-out disinfection nozzles in the middle, which can be extended up to 3.20 m when used and then the UV-C light and the disinfectant are optimally distributed in the room.
In order to implement the project as quickly as possible, for which a development period of 3 to 6 months is planned until series production starts, the Board of Directors of Swiss Robot AG has decided to increase the capital by up to 10 million new shares at $ 3 per share and to offer up to 5 million shares via the Crowdfunder platform to interested investors. The minimum deposit is $ 3000. When the minimum amount of $ 2 million is reached, the project starts immediately. For the intended IPO of SWISS ROBOT AG in 2022/2023 and the implementation of the business plan, a share issue price of min. CHF 20 can be a realistic goal.The planned annual production for 2020 with 100 FTS Medical robots is completely reserved for Swiss hospitals and clinics. The management, designers, programmers, production facilities and production personnel are ready to go in Switzerland.
Below is an excerpt from a standard text for crowdfunding platforms without further comment on our part.
What are some of the risks involved in investing?
Please be sure to carefully review the Risk Disclosures. The following section is excerpted from that lengthier document.
Some of the key risks to know before you invest in startups:
Crowdfunding investments are highly risky and speculative. You should do your own research and scrutinize all disclosed risk factors before making an investment decision. The following are some of the key risks applicable to Republic offerings:
Speculative: Investments in startups and early-stage ventures are speculative and these enterprises often fail. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or
service that may or may not find a market. You should be prepared to lose your entire investment.
Illiquidity: Your ability to resell your investment in the first year will be restricted with narrow exceptions. You may need to hold your investment for an indefinite period of time. Unlike investing in companies listed on a stock exchange where you can quickly and easily trade securities, you may have to locate an interested private buyer when you do seek to resell your crowdfunded investment.
No voting rights: A Crowdfunding Investment does not provide voting rights to its holder, unless and until the Crowdfunding Investment or the note is converted into an equity stake. If and when you receive voting shares in a company, your voting rights will likely be diluted when the company raises additional funds.
Cancellation restrictions: Once you make an investment in a crowdfunding offering, you can cancel the investment at any time and for any reason up to 48 hours before the offering deadline.
Valuation and capitalization: Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult. You risk overpaying for the equity stake you receive. The class of equity being sold via a crowdfunding offering may have fewer rights than other equity classes issued by a company.
Limited disclosure: The company must disclose information about itself, its business plan, the offering, and its anticipated use of proceeds, among other things. An early-stage company may be able to provide only limited information about its business plan and operations because it does not have fully developed operations or a long history to provide more disclosure. The company is also only obligated to file information regarding its business annually, including financial statements.
Under certain circumstances the company may cease to publish annual reports and holders of the Crowd SAFE will have no information rights.
Investment in personnel: An early-stage investment is also an investment in the founding entrepreneur(s) and/or management of the company. Being able to execute on the business plan is often an important factor determining whether the business will be viable and successful. You should also be aware that a portion of your investment may fund the compensation of the company’s employees, including its management. You should carefully review any disclosure regarding the company’s use of proceeds.
Possibility of fraud: As with other investments, there is no guarantee that crowdfunding investments will be immune from fraud.